Brief: Akari Therapeutics Announces Establishment Of Boston U.S. Headquarters Office

Akari Therapeutics

18/08/2023 15:03

Aug 18 (Reuters) - Akari Therapeutics PLC  AKTX.O :
    * AKARI THERAPEUTICS ANNOUNCES ESTABLISHMENT OF BOSTON U.S.
HEADQUARTERS OFFICE TO SUPPORT EXPANDING OPERATIONS AND START OF
REGISTRATIONAL PHASE 3 CLINICAL TRIALS
    * AKARI THERAPEUTICS PLC - START OF CLINICAL TRIALS OF
LONG-ACTING
PAS-NOMACOPAN AS A POTENTIAL TREATMENT FOR GA IS ANTICIPATED IN
2024
    * AKARI THERAPEUTICS- ENROLLMENT IN PHASE 3 CLINICAL TRIALS
OF
NOMACOPAN IN PEDIATRIC & ADULT HSCT-TMA IS EXPECTED TO BEGIN IN
LATE 2023 & 2024, RESPECTIVELY

Source text for Eikon:  ID:nGNX8k1fHN 
Further company coverage:  AKTX.O 

 ((Reuters.Briefs@thomsonreuters.com;))